Health Economics›Subependymal giant cell astrocytoma›All lines of therapy

All lines of therapy

Subependymal giant cell astrocytoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~7	~R 128 518 PFS proxy · indirect	15
Placebo Partial	—	—	—	~11.3 mo	—	—	—	2

2 of 2 regimens shown